Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Accumulated Expenses (2023 - 2026)

ArriVent BioPharma has reported Accumulated Expenses over the past 4 years, most recently at $14.1 million for Q1 2026.

  • Quarterly results put Accumulated Expenses at $14.1 million for Q1 2026, up 811.81% from a year ago — trailing twelve months through Mar 2026 was $14.1 million (up 811.81% YoY), and the annual figure for FY2025 was $20.0 million, up 50.02%.
  • Accumulated Expenses reached $14.1 million in Q1 2026 per AVBP's latest filing, down from $20.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $20.0 million in Q4 2025 and bottomed at $1.0 million in Q1 2024.
  • Median Accumulated Expenses over the past 4 years was $10.6 million (2024), compared with a mean of $9.6 million.
  • The largest annual shift saw Accumulated Expenses increased 4.48% in 2025 before it soared 811.81% in 2026.
  • Over 4 years, Accumulated Expenses stood at $3.4 million in 2023, then surged by 297.55% to $13.3 million in 2024, then skyrocketed by 50.02% to $20.0 million in 2025, then decreased by 29.37% to $14.1 million in 2026.
  • Business Quant data shows Accumulated Expenses for AVBP at $14.1 million in Q1 2026, $20.0 million in Q4 2025, and $10.8 million in Q3 2025.